An Author Webinar on the Disability Assessment of Dementia (DAD)
December 7 @ 10:00 - 11:00 UTC+0
Dr. Isabelle Gélinas, Ph.D., OT(c), erg. - DAD Author; Associate Professor l Graduate Program Director l Director of the Graduate Certificate Programs; Researcher l Centre de recherche interdisciplinaire en réadaptation du Montréal métropolitain & CanDRIVE - Driving research for older adults; McGill University l School of Physical and Occupational Therapy; Davis House l 3654 Prom. Sir William Osler l Montreal, Quebec H3G 1Y5
Dr Gélinas is an Associate Professor, Graduate Program Director and Director of the Graduate Certificate Programs at McGill University School of Physical and Occupational Therapy in Montreal, Canada. Dr Gélinas' research focuses on the activities and the contextual factors (personal and environmental) that shape the level of social participation of adults and elderly with disability. More specifically, her research encompasses two main domains: Driving rehabilitation and Activities of Daily Living. Presently her research projects are directed at: 1) the assessment and training of driving abilities in seniors and in clients with disabilities, 2) the development of daily living assessment in persons with disabling conditions, 3) the development and the evaluation of intervention strategies to improve the participation and social inclusion of persons with a disability
- Gauthier Louise; Gelinas Isabelle
- DAD © 1994 by L. Gauthier & I. Gélinas
- To quantitatively measure functional abilities in activities of daily living (ADL) in individuals with cognitive impairments such as dementia
- Nervous System Diseases
- Mental Disorders
- Alzheimer Disease
- Nervous System Diseases
- English for Canada
- French for Canada
The DAD, a 40-item questionnaire originally published by Dr Gélinas and Professor Gauthier in 1999, has since then become a reference instrument to quantitatively measure functional abilities in activities of daily living (ADL) in individuals with cognitive impairments such as dementia. During this webinar, the author of the health research questionnaire will provide attendees with a brief description of the DAD and how the instrument can be applied to clinical practice. Learn more by attending this upcoming webinar! Register now to join us for the live event.
Click the registrations tab to register to attend today at no cost to you!
- Have a look at this press release - Mapi Research Trust selected as exclusive distributor and Mapi Language Services selected as exclusive translator of the Disability Assessment for Dementia (DAD)
- The DAD at the ASCP conference in Miami // 28-Apr-2017 09:38 // The Disability Assessment for Dementia (DAD) will be at the heart of a Panel Session titled "Validly and Reliably Measuring Functional Performance in Dementia Patients Across Countries and Languages in Clinical Trials" at the next Annual American Society for Clinical Psychopharmacology (ASCP) Meeting held May 29 – June 2, 2017 in Miami, Florida.
- eProvide Listing of the Disability Assessment for Dementia (DAD) [Authors: Gauthier Louise; Gelinas Isabelle]: https://eprovide.mapi-trust.org/instruments/disability-assessment-for-dementia >> For any request about the DAD or to view the DAD's description, please consult https://eprovide.mapi-trust.org/
More Information About Mapi Language Services & Mapi Research Trust:
Mapi Language Services is the worldwide leader in medical translation and Linguistic Validation of COAs for more than 25 years. Mapi has first-hand knowledge of local languages and cultures, regulations, and healthcare practices. We work in close collaboration with developers, assure conceptual equivalence and international harmonization of all language versions. Mapi Language Services' experience represents more than 40,000 translated versions of 2,500 Questionnaires in 170 languages.
Mapi Research Trust is the largest curator of Clinical Outcomes Assessments (COA) and their translations, the largest single COA licensing provider and the most trusted name in distribution of COA instruments exclusively representing over 280 exclusive questionnaires. As the worldwide leader in translation and linguistic validation of COAs for more than 25 years, Mapi's experience represents more than 40,000 translated versions of 2,500 Questionnaires in 170 languages.
Patient Insights & Engagement Webinar – Creating Tools that are Share-worthy: Encouraging Patient Centricity throughout the OrganizationAugust 31, 2018 @ 10:00 - 11:00 UTC+0
PCO Webinar – Developing PROs to support labelling claims, especially for rare diseases/specialty productsSeptember 7 @ 09:00 - 10:00 UTC+0
November 15 @ 10:00 - 17:00 UTC+0
- A Real World Strategy & Analytics Webinar: Challenges and solutions for Risk Management Plan (RMP) Effectiveness Studies
- An Author Webinar on the Disease Activity Score (DAS/DAS-28)
- Rare Disease Webinar: SYNGAP Education & Research – Collaboration & Data sharing as Keys to Progress
- Direct to Patient Contact Webinar: How Routine Patient Contact Reduces Patient Loss & Costs in Long-Term Studies
- RAPS Philadelphia Chapter Regulatory Webinar: Pitfalls to Avoid for CMC Postapproval Changes
- PCO Accept Webinar: Do you know how motivated patients affected by multiple sclerosis are to take treatment & why they are not?
- Database Analyses: Linking Administrative Registries with Clinical Registries
- Health Policy Initiatives: Ideas Becoming Official Policy and Beyond
- View All Archived Webinars
- Forúm Assistência Farmacêutica e Farmacoeconomia / V Brazilian Forum On Pharmaceutical Assistance And Pharmacoeconomics: The Financing Of Pharmaceutical Assistance In Times Of Crisis
- ISPE’s 33rd International Conference on Pharmacoepidemiology (ICPE) & Therapeutic Risk Management 2017
- ISCTM 2017 Autumn Conference
- PCO Webinar – Developing PROs to support labelling claims, especially for rare diseases/specialty products
- 2017 RAPS Regulatory Convergence
- PCO ACCEPT Webinar Series – Session 3: Do you know how much patients affected by Rheumatoid Arthritis or Crohn’s Disease or Psoriasis are motivated to take treatment and why they are not?
- Mapi and Saama Create Actionable Solutions From Recent Strategic Alliance
- Press Release: Mapi Creates Dedicated Patient Centered Sciences Unit by Combining Patient Centered Outcomes, Patient Insights and Engagement and Direct To Patient Contact Services
- Mapi Research Trust and Mapi Language Services present scientific research works at the International Congress of Parkinson’s Disease and Movement Disorders (MDS)
- Press Release: Mapi Continues Organic Growth and Expansion in the United Kingdom
- Mapi Research Trust selected as exclusive distributor and Mapi Language Services selected as exclusive translator of the Disability Assessment for Dementia (DAD)